Dyadic International, Inc.

158 articles with Dyadic International, Inc.

• Dyadic International to Webcast, Live, at VirtualInvestorConferences.com April 4th

  4/1/2019

  Dyadic International, Inc. (the "Company") (OTCQX: DYAI), , today announced that its President and Chief Executive Officer, Mark Emalfarb will present live at VirtualInvestorConferences.com on April 4th.

• 

  From “Jeans to Genes”: Mark Emalfarb Thinks He Can Revolutionize Biopharma Manufacturing

  8/7/2018

  Mark Emalfarb, founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International, believes he knows how to revolutionize biopharma manufacturing. Emalfarb took time out to talk to BioSpace about his company and its C1 technology platform.

• Dyadic International Announces Research and Development Collaboration to Produce An Active Ingredient in C1

  2/7/2018

  The deal will explore the potential of its C1 technology to produce an important active moiety with an integrated, global biotech company.

• Dyadic International Announces Research and Development Collaboration With the Israel Institute for Biological Research (IIBR) to Combat Emerging Diseases & Threats

  1/16/2018

  IIBR is a governmental, applied research institute specializing in the fields of biology, medicinal chemistry and environmental sciences.

• Dyadic International Reports Third Quarter 2017 Financial Results

  11/10/2017

  Management will host a conference call to discuss the financial results for the quarter ended September 30, 2017.

• Dyadic International to Announce Third Quarter 2017 Financial Results and Host Conference Call on Thursday November 9, 2017

  10/27/2017

  A conference call will be held at 5:00 p.m. Eastern Time to discuss those results.

• Dyadic Announces $5 Million Stock Repurchase Program

  8/17/2017

• Dyadic Reports Second Quarter 2017 Financial Results

  8/11/2017

• Dyadic Announces The Conclusion Of Its Research Services Agreement With DuPont

  8/7/2017

• Dyadic To Announce Second Quarter 2017 Financial Results And Host Conference Call On Thursday August 10, 2017

  7/28/2017

• Dyadic Announces An Important Multi-Year Research And Development Arrangement To Further Advance Its Proprietary C1 Technology

  7/10/2017

• Dyadic Announces Board Members Share Purchase

  5/26/2017

• Dyadic Reports First Quarter 2017 Financial Results

  5/12/2017

• Dyadic To Announce First Quarter 2017 Financial Results And Host Conference Call On Thursday, May 11, 2017

  4/28/2017

• Dyadic Claims Bad Legal Advice Cost The Company $700 Million In Lost Business

  1/12/2017

• Dyadic Stock Tanks Amid Reports of Partnership Termination With Sanofi Pasteur

  8/9/2016

• Dyadic Reports 2015 Annual Financial Results

  3/30/2016

• Former Iowa Wrestler Divests Dyadic's Enzyme Tech for $75 Million

  11/30/2015

• Dyadic To Present At The 4th International Conference On Biologics And Biosimilars

  10/9/2015

• Dyadic International, Inc. Receives C1 Derived Vaccine Test Results From Sanofi Pasteur And Provides Further Details On New EU-Funded ZAPI Biopharmaceutical Program

  10/7/2015